February 28, 2023
Daiichi Sankyo and AstraZeneca said on February 24 that their antibody drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) was approved in China for the treatment of certain patients with HER2 positive breast cancer. The drug gained the nod as a monotherapy...read more